These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10210138)

  • 1. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
    Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J
    Hum Gene Ther; 1999 Mar; 10(5):697-709. PubMed ID: 10210138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.
    Palmer K; Hitt M; Emtage PC; Gyorffy S; Gauldie J
    Gene Ther; 2001 Feb; 8(4):282-90. PubMed ID: 11313802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
    Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
    J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells.
    Emtage PC; Xing Z; Wan Y; Zlotnik A; Graham FL; Gauldie J
    J Interferon Cytokine Res; 2002 May; 22(5):573-82. PubMed ID: 12060496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.
    Liu Y; Huang H; Saxena A; Xiang J
    Cancer Gene Ther; 2002 Jun; 9(6):533-42. PubMed ID: 12032664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
    Rousseau RF; Haight AE; Hirschmann-Jax C; Yvon ES; Rill DR; Mei Z; Smith SC; Inman S; Cooper K; Alcoser P; Grilley B; Gee A; Popek E; Davidoff A; Bowman LC; Brenner MK; Strother D
    Blood; 2003 Mar; 101(5):1718-26. PubMed ID: 12406881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.
    Emtage PC; Wan Y; Muller W; Graham FL; Gauldie J
    J Interferon Cytokine Res; 1998 Nov; 18(11):927-37. PubMed ID: 9858314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
    Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL
    Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer.
    Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL
    Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
    Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI
    Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
    Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
    Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
    Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
    Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
    Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
    Huang H; Xiang J
    Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.